ArticleiScience2024
Humoral correlates of protection against
Abstract read
In one paragraph
Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Route of BCG administration determines success.Human vaccines & immunotherapeutics · 2026Review
- ESAT-6-derived lipopeptide-based mucosal vaccine elicits distinct humoral immune responses concomitant with a reduction inEmerging microbes & infections · 2026Article
- Transcriptional analyses of peripheral blood lymphocytes obtained shortly after primary immunization discriminate vaccines againstInfection and immunity · 2026Article
- Review
- Mucosal BCG Vaccination and Immune Layering: Route-Dependent Programming of Immunity at the Respiratory Interface.Vaccines · 2026Review
- mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges.Archives of microbiology · 2026Review
- Immunological mechanistic action of intravenous BCG-mediated protection against tuberculosis.Cellular and molecular life sciences : CMLS · 2026Review
- BCG vaccination reduces the rate of Mycobacterium tuberculosis dissemination between murine lungs.Research square · 2026Article
- BCG vaccination reduces the rate of Mycobacterium tuberculosis dissemination between murine lungs.bioRxiv : the preprint server for biology · 2026Article
- Cross-species blood transcriptional correlates of BCG-mediated protection against tuberculosis include innate and adaptive immune processes.JCI insight · 2025Article
- Novel Multistage SubunitVaccines · 2025Article
- The BCGMethodsX · 2025Article
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- BCG Vaccine-Induced Innate and Adaptive Pulmonary Immunity Correlating with Protective Efficacy AgainstVaccines · 2025Article
- TnSeq identifies genetic requirements of Mycobacterium tuberculosis for survival under vaccine-induced immunity.NPJ vaccines · 2025Article
- Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes.The Journal of experimental medicine · 2025Article
- Deconvoluting the interplay of innate and adaptive immunity in BCG-induced nonspecific and TB-specific host resistance.The Journal of experimental medicine · 2025Review
- Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.Nature microbiology · 2025Article
- Experimental dissection of tuberculosis protective immunity: a human perspective.Frontiers in cellular and infection microbiology · 2025Review
- Markov field network model of multi-modal data predicts effects of immune system perturbations on intravenous BCG vaccination in macaques.Cell systems · 2024Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Edward B IrvineRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Patricia A DarrahVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.
Shu WangDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Chuangqi WangDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ryan P McNamaraRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
JoAnne L FlynnDepartment of Microbiology and Molecular Genetics and Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Sarah M FortuneRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Funding
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)75N93019C00071 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI FORTUNE, SARAH · 2019 to 2025
$57.3MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SHARPE, ARLENE H. · 2018 to 2022
$10.8MOmic and Multidimensional Spatial Atlas of Metastatic Breast CancerU2CCA233280 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOECKS, JEREMY · 2018 to 2023
$9.7MPre-cancer atlases of cutaneous and hematologic origin (PATCH Center)U2CCA233262 · NCI · HARVARD MEDICAL SCHOOL · PI SANTAGATA, SANDRO · 2018 to 2023
$8.7MExploiting Fc-engineering to dissect mechanisms of anti-microbial action of M. tuberculosis-specific antibodiesF31AI150171 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI IRVINE, EDWARD BUFORD · 2020 to 2021
$64kNCI NIH HHS U2C CA233262NCI NIH HHS U2C CA233280NCI NIH HHS U54 CA225088NIAID NIH HHS 75N93019C00071NIAID NIH HHS F31 AI150171
Abstract
Altering Bacille Calmette-Guérin (BCG) immunization from low-dose intradermal (i.d.) to high-dose intravenous (i.v.) vaccination provides a high level of protection against
Indexed as
Health sciencesImmunologyPathophysiology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.